Net loss of $4.1 million or $0.58 per share Read more…
Offering of 1,083,334 units at a price of $3.00 per unit, for gross proceeds of $3.25 M Read more…
To develop and commercialize Tcelna (imilecleucel-T), an investigational T-cell therapy for patients suffering from multiple sclerosis (MS) Read more…
A P2b clinical trial of Tcelna Read more…
A net loss of $2.16M or $0.09 per share Read more…
I have recently learned that Opexa has changed the name of their lead drug candidate from Tovaxin to Tcelna. Read more…
Net loss of $2.37M or $0.10 per share Read more…
FY11 net loss of $5,968,448, or $0.26 per share Read more…
OPXA’s Tovaxin® has been granted Fast Track designation by the FDA Read more…
A net loss of $1.49M or $0.06 per share Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.